Literature DB >> 33898570

Heterogeneity in neoadjuvant therapy for localized pancreatic cancer: a persisting radiant autonomy.

Kjetil Søreide1,2,3.   

Abstract

Entities:  

Year:  2021        PMID： 33898570      PMCID： PMC8050584          DOI： 10.21037/hbsn-2020-9

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  11 in total

1.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 3.  Trials and tribulations of neoadjuvant therapy in pancreatic cancer.

Authors:  M Del Chiaro; K Søreide
Journal:  Br J Surg       Date:  2018-10       Impact factor: 6.939

4.  Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

Authors:  Eva Versteijne; Mustafa Suker; Karin Groothuis; Janine M Akkermans-Vogelaar; Marc G Besselink; Bert A Bonsing; Jeroen Buijsen; Olivier R Busch; Geert-Jan M Creemers; Ronald M van Dam; Ferry A L M Eskens; Sebastiaan Festen; Jan Willem B de Groot; Bas Groot Koerkamp; Ignace H de Hingh; Marjolein Y V Homs; Jeanin E van Hooft; Emile D Kerver; Saskia A C Luelmo; Karen J Neelis; Joost Nuyttens; Gabriel M R M Paardekooper; Gijs A Patijn; Maurice J C van der Sangen; Judith de Vos-Geelen; Johanna W Wilmink; Aeilko H Zwinderman; Cornelis J Punt; Casper H van Eijck; Geertjan van Tienhoven
Journal:  J Clin Oncol       Date:  2020-02-27       Impact factor: 44.544

5.  Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.

Authors:  Jin-Young Jang; Youngmin Han; Hongeun Lee; Sun-Whe Kim; Wooil Kwon; Kyung-Hun Lee; Do-Youn Oh; Eui Kyu Chie; Jeong Min Lee; Jin Seok Heo; Joon Oh Park; Do Hoon Lim; Seong Hyun Kim; Sang Jae Park; Woo Jin Lee; Young Hwan Koh; Joon Seong Park; Dong Sup Yoon; Ik Jae Lee; Seong Ho Choi
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

Review 6.  Meta-analysis of recurrence pattern after resection for pancreatic cancer.

Authors:  M Tanaka; A L Mihaljevic; P Probst; M Heckler; U Klaiber; U Heger; M W Büchler; T Hackert
Journal:  Br J Surg       Date:  2019-08-27       Impact factor: 6.939

7.  Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation.

Authors:  J Kirkegård; E K Aahlin; M Al-Saiddi; S O Bratlie; M Coolsen; R J de Haas; M den Dulk; C Fristrup; E M Harrison; M B Mortensen; M W Nijkamp; J Persson; J A Søreide; S J Wigmore; T Wik; F V Mortensen
Journal:  Br J Surg       Date:  2019-03-04       Impact factor: 6.939

8.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).

Authors:  Fuyuhiko Motoi; Tomoo Kosuge; Hideki Ueno; Hiroki Yamaue; Sohei Satoi; Masayuki Sho; Goro Honda; Ippei Matsumoto; Keita Wada; Junji Furuse; Yutaka Matsuyama; Michiaki Unno
Journal:  Jpn J Clin Oncol       Date:  2019-02-01       Impact factor: 3.019

Review 9.  Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why?

Authors:  Jessica E Maxwell; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2020-11-17       Impact factor: 3.452

10.  Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer.

Authors:  Scott Kizy; Ariella M Altman; Keith M Wirth; Schelomo Marmor; Jane Y C Hui; Todd M Tuttle; Emil Lou; Khalid Amin; Jason W Denbo; Eric H Jensen
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.